Literature DB >> 17671637

Treatment for chronic myelogenous leukemia: the long road to imatinib.

Tony Hunter1.   

Abstract

The scientists of today have become accustomed to the extremely rapid pace of progress in the biomedical sciences spurred on by the discovery of recombinant DNA and the advent of automated DNA sequencing and PCR, with progress usually being measured in months or years at most. What is often forgotten, however, are the many prior advances that were needed to reach our present state of knowledge. Here I illustrate this by discussing the scientific discoveries made over the course of the past century and a half that ultimately led to the recent successful development of drugs, particularly imatinib mesylate, to treat chronic myelogenous leukemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671637      PMCID: PMC1934577          DOI: 10.1172/JCI31691

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  106 in total

1.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

Authors:  E Buchdunger; C L Cioffi; N Law; D Stover; S Ohno-Jones; B J Druker; N B Lydon
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

2.  Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.

Authors:  A W Gross; X Zhang; R Ren
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

3.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

Authors:  Charles L Sawyers; Andreas Hochhaus; Eric Feldman; John M Goldman; Carole B Miller; Oliver G Ottmann; Charles A Schiffer; Moshe Talpaz; Francois Guilhot; Michael W N Deininger; Thomas Fischer; Steve G O'Brien; Richard M Stone; Carlo B Gambacorti-Passerini; Nigel H Russell; Jose J Reiffers; Thomas C Shea; Bernard Chapuis; Steven Coutre; Sante Tura; Enrica Morra; Richard A Larson; Alan Saven; Christian Peschel; Alois Gratwohl; Franco Mandelli; Monique Ben-Am; Insa Gathmann; Renaud Capdeville; Ronald L Paquette; Brian J Druker
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

4.  The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.

Authors:  X Zhang; R Wong; S X Hao; W S Pear; R Ren
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

5.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Authors:  T Schindler; W Bornmann; P Pellicena; W T Miller; B Clarkson; J Kuriyan
Journal:  Science       Date:  2000-09-15       Impact factor: 47.728

6.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

Review 7.  Arsenic trioxide, a therapeutic agent for APL.

Authors:  T D Zhang; G Q Chen; Z G Wang; Z Y Wang; S J Chen; Z Chen
Journal:  Oncogene       Date:  2001-10-29       Impact factor: 9.867

8.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

9.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Authors:  B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

10.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

View more
  37 in total

Review 1.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 2.  The legacy of the Philadelphia chromosome.

Authors:  Gary A Koretzky
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

3.  Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers.

Authors:  Yong-Hun Lee; William P Schiemann
Journal:  Breast Cancer Manag       Date:  2014

Review 4.  The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells.

Authors:  Tressa M Allington; William P Schiemann
Journal:  Cells Tissues Organs       Date:  2010-11-03       Impact factor: 2.481

Review 5.  Protein glycosylation in cancer.

Authors:  Sean R Stowell; Tongzhong Ju; Richard D Cummings
Journal:  Annu Rev Pathol       Date:  2015       Impact factor: 23.472

6.  Mechanism of dietary salt-mediated increase in intravascular production of TGF-beta1.

Authors:  Wei-Zhong Ying; Kristal Aaron; Paul W Sanders
Journal:  Am J Physiol Renal Physiol       Date:  2008-06-18

7.  RuleMonkey: software for stochastic simulation of rule-based models.

Authors:  Joshua Colvin; Michael I Monine; Ryan N Gutenkunst; William S Hlavacek; Daniel D Von Hoff; Richard G Posner
Journal:  BMC Bioinformatics       Date:  2010-07-30       Impact factor: 3.169

8.  A phosphotyrosine switch determines the antitumor activity of ERβ.

Authors:  Bin Yuan; Long Cheng; Huai-Chin Chiang; Xiaojie Xu; Yongjian Han; Hang Su; Lingxue Wang; Bo Zhang; Jing Lin; Xiaobing Li; Xiangyang Xie; Tao Wang; Rajeshwar R Tekmal; Tyler J Curiel; Zhi-Min Yuan; Richard Elledge; Yanfen Hu; Qinong Ye; Rong Li
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

Review 9.  The relevance of the TGF-β Paradox to EMT-MET programs.

Authors:  Chevaun D Morrison; Jenny G Parvani; William P Schiemann
Journal:  Cancer Lett       Date:  2013-03-05       Impact factor: 8.679

10.  ChimerDB 2.0--a knowledgebase for fusion genes updated.

Authors:  Pora Kim; Suhyeon Yoon; Namshin Kim; Sanghyun Lee; Minjeong Ko; Haeseung Lee; Hyunjung Kang; Jaesang Kim; Sanghyuk Lee
Journal:  Nucleic Acids Res       Date:  2009-11-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.